Affiliation:
1. Department of Medical Microbiology, Faculty of Medicine
2. Departments of Medicine
3. Clinical Microbiology, Health Sciences Centre
4. Nosocomial Infections Branch, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
5. Department of Clinical Microbiology, St. Boniface General Hospital
6. Department of Chemistry, Faculty of Science, University of Manitoba
7. International Health Management Associates, Chicago, Illinois
Abstract
ABSTRACT
A total of 5,282 bacterial isolates obtained between 1 January and 31 December 31 2008, inclusive, from patients in 10 hospitals across Canada as part of the Canadian Ward Surveillance Study (CANWARD 2008) underwent susceptibility testing. The 10 most common organisms, representing 78.8% of all clinical specimens, were as follows:
Escherichia coli
(21.4%), methicillin-susceptible
Staphylococcus aureus
(MSSA; 13.9%),
Streptococcus pneumoniae
(10.3%),
Pseudomonas aeruginosa
(7.1%),
Klebsiella pneumoniae
(6.0%), coagulase-negative staphylococci/
Staphylococcus epidermidis
(5.4%), methicillin-resistant
S. aureus
(MRSA; 5.1%),
Haemophilus influenzae
(4.1%),
Enterococcus
spp. (3.3%),
Enterobacter cloacae
(2.2%). MRSA comprised 27.0% (272/1,007) of all
S. aureus
isolates (genotypically, 68.8% of MRSA were health care associated [HA-MRSA] and 27.6% were community associated [CA-MRSA]). Extended-spectrum β-lactamase (ESBL)-producing
E. coli
occurred in 4.9% of
E. coli
isolates. The CTX-M type was the predominant ESBL, with CTX-M-15 the most prevalent genotype. MRSA demonstrated no resistance to ceftobiprole, daptomycin, linezolid, telavancin, tigecycline, or vancomycin (0.4% intermediate intermediate resistance).
E. coli
demonstrated no resistance to ertapenem, meropenem, or tigecycline. Resistance rates with
P. aeruginosa
were as follows: colistin (polymyxin E), 0.8%; amikacin, 3.5%; cefepime, 7.2%; gentamicin, 12.3%; fluoroquinolones, 19.0 to 24.1%; meropenem, 5.6%; piperacillin-tazobactam, 8.0%. A multidrug-resistant (MDR) phenotype occurred frequently in
P. aeruginosa
(5.9%) but uncommonly in
E. coli
(1.2%) and
K. pneumoniae
(0.9%). In conclusion,
E. coli
,
S. aureus
(MSSA and MRSA),
P. aeruginosa
,
S. pneumoniae
,
K. pneumoniae
,
H. influenzae
, and
Enterococcus
spp. are the most common isolates recovered from clinical specimens in Canadian hospitals. The prevalence of MRSA was 27.0% (of which genotypically 27.6% were CA-MRSA), while ESBL-producing
E. coli
occurred in 4.9% of isolates. An MDR phenotype was common in
P. aeruginosa.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology